University Hospital Ghent
Ghent, 9000, Belgium
Location status: Recruiting
Location contact
Peter De Paepe, Prof. Dr.
CONTACT
Tania Desmet, Dr.
CONTACT
NCT Number: NCT04436991
In this pilot study, we will investigate whether - with the current dosing regimens, used in the Ghent University Hospital - pharmacodynamic targets regarding beta-lactam antibiotics (more specific Amoxicilline-Clavulanate, Piperacillin-Tazobactam and Temocillin) are attained in frail patients admitted to the geriatric department.
Interested in participating?
Request Info75 year and older
All sexes
Observational
Ghent, 9000, Belgium
Location status: Recruiting
Peter De Paepe, Prof. Dr.
CONTACT
Tania Desmet, Dr.
CONTACT
In drug research studies, older people - and especially patients with a geriatric profile or frailty risk - are very frequently excluded. Moreover, drug dosing is often extrapolated from studies in younger adults with failure to consider potential differences in pharmacokinetics (PK) and pharmacodynamics (PD).
Studies on dosing of beta-lactam antibiotics in geriatric or frail patients aged 75 years or older have, to the best of our knowledge, never been performed.
In this pilot study, we will investigate whether - with the current dosing regimens, used in the Ghent University Hospital - pharmacodynamic targets regarding beta-lactam antibiotics (more specific Amoxicilline-Clavulanate, Piperacillin-Tazobactam and Temocillin) are attained in frail patients admitted to the geriatric department.
This monocentric, prospective, observational trial is currently ongoing at the emergency department and geriatric department of the Ghent University Hospital.
Amoxicillin/clavulanic acid 1000/200mg of piperacillin-tazobactam 4000mg or temocillin 2000mg was infused intravenously over 30 minutes using a syringe pump. The standard dosing regimes were used.
An infusion catheter of minimum 18-gauge was placed in the contralateral arm to the arm in which the antibiotic dose was administered. Blood samples were collected from this catheter at first dose and assumed steady state conditions. Steady state was assumed to be reached after minimal 24h (> 4 doses at four - six hourly interval) of therapy. The goal was to obtain 5 first dose and 5 steady dose samples in every patient.
Material for bacteriological analysis, such as blood cultures, urine samples, sputum, were collected in every patient according to standard care. In case of bacterial growth, MIC's were measured on the reported strains when possible.
Amoxicillin, clavulanic acid, piperacillin, tazobactam and temocillin were measured using a validated ultra-performance liquid chromatographic method with tandem mass spectrometric detection.
Serum creatinine, cystatin C, procalcitonin, infection parameters (CRP, WBC count) and albumin were obtained from standard blood samples performed in these patients at day one and also later on during their therapy.
Three frailty score systems (KATZ, Geriatric 8 - G8, Cumulative Illness Rating Scale - CIRS) were calculated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
At predefined time points through a venous catheter already in place. Max. volume to be withdrawn: Maximum 4ml/sample. Maximum 10 samples/patient.
A last blood sample will be taken, if necessary, after the end of antibiotic therapy, between day 7 and day 14. Though blood results preferably will be used from available data from tests already done during standard treatment.
Samples are collected in lithium-heparin tubes (without gel) and centrifuged immediately (within a maximum of 30 minutes after sampling) at room temperature: 8 minutes at 1885g.
Plasma is then collected and divided in two separated labelled Eppendorf tubes 1.5 ml and immediately frozen at - 80 °C. If this is not immediately possible, tubes are frozen at - 20 °C and at regular time points transferred to a freezer at - 80 °C (minimum twice a day).
Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
Time frame: Within the first 12 hours (early dose) of treatment and after 24 - 48 hours of treatment (steady state)
To investigate whether blood concentrations with maximum antimicrobial activity are achieved with current dosing regimens in first-dose or early-dose conditions and in steady-state conditions.
Time frame: Within the first 12 hours (early dose) of treatment and after 24 - 48 hours of treatment (steady state)
To investigate whether blood concentrations with maximum antimicrobial activity are achieved with current dosing regimens in first-dose or early-dose conditions and in steady-state conditions.
Time frame: Within the first 12 hours (early dose) of treatment and after 24 - 48 hours of treatment (steady state)
To investigate whether blood concentrations with maximum antimicrobial activity are achieved with current dosing regimens in first-dose or early-dose conditions and in steady-state conditions.
Time frame: Within the first 12 hours (early dose) of treatment and after 24 - 48 hours of treatment (steady state)
To compare measured total and unbound concentrations of beta-lactam antibiotics with predefined pharmacodynamic targets.
Time frame: The end of individual antibiotic therapy with an average of 1 week
To describe therapeutic response to antimicrobial therapy using procalcitonin.
Time frame: The end of individual antibiotic therapy with an average of 1 week
To compare achievement of pharmacodynamic targets in early-dose and steady-state conditions.
Time frame: Within the first 12 hours (early dose) of treatment and after 24 - 48 hours of treatment (steady state)
To compare clearance of betalactam antibiotics and correlate with renal function using creatinin clearance en cystatin C.
Contact information is provided by the study sponsor or research team.
Peter De Paepe, Prof. Dr.
CONTACT
Tania Desmet, Dr.
CONTACT
University Hospital, Ghent
Other
Acronym: AGED
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04734431
Bacterial Infections, Bacterial Infections and Mycoses
Garches, France
View Trial DetailsNCT04385212
Coronaviridae Infections, Coronavirus Infection
Geneva, Switzerland
View Trial DetailsNCT06717581
Blood-Borne Infections, Cardiovascular Diseases
Bologna, Italy
View Trial DetailsNCT07070284
Community-Acquired Infections, Community-Acquired Pneumonia
Zagreb, City of Zagreb, Croatia
View Trial Details